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Abstract – 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, yet no 
treatment effectively prevents, halts or reverses the disease.  Progress in developing treatments is 
hampered by the extensive time required for traditional mouse models of AD to age before 
displaying histological hallmarks of AD. We set out to test whether a novel transgenic model of 
AD using the nematode Caenorhabditis elegans may be used to more rapidly determine efficacy 
of candidate treatments through high throughput screening of behaviors.  Our lab previously 
showed that antagonists for the conserved Sigma-2 receptor (Sig2R) are protective against age-
dependent degeneration of cholinergic neurons caused by the human plaque protein, amyloid 
precursor protein (APP), in this model.  To investigate how inhibition of Sig2R protects neurons, 
we tested whether knockdown of Sig2R via RNA interference prevented decline of two 
behaviors that depend on these cholinergic neurons.  We found that RNAi treatment normalized 
one of the two behaviors in this AD model suggesting that the antagonists act against the Sig2R 
in vivo for neuroprotection.  The success of this study suggests that this behavioral readout might 
be used to screen for additional pharmaceutical and genetic modifiers of Sig2R on 
neurodegeneration.  In addition to developing this high throughput behavioral screening, we also 
built transgene components to generate an improved second generation C. elegans model of AD 
that conveniently tags the APP protein with mCherry for in vivo fluorescent visualization.  Our 




Alzheimer’s disease (AD) has been a devastating challenge to the research, medical, and 
public community for more than a century.  In 1906, AD was described as a neurodegenerative 
disorder associated with progressive cognitive and memory impairment.  Nearly a century later, 
the etiology of AD remains unknown and there is no treatment to effectively prevent, halt, or 
reverse the disease.1  Mitochondrial and endoplasmic reticulum (ER) driven apoptosis has been 
implicated in disease-specific protein accumulation during the early-stages of AD pathogenesis.1  
Research now focuses on identifying both the molecular mechanism of the disease and potential 
biological targets for therapeutic drugs that will inhibit abnormal protein accumulation in the 
brain and improve cognitive function.  
Protein misfolding and ER stress contribute to AD-related degeneration in a subset of 
cholinergic neurons important for memory.  In particular, β-amyloid (Aβ) peptide accumulates in 
senile plaques within the brain of AD patients due to abnormal processing of the amyloid 
precursor protein (APP).2  Identical plaques also form in the brains of those with Down 
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Syndrome because these individuals carry an extra copy of the human APP gene on chromosome 
21. More than 75 percent of individuals in this population develop early-onset AD.3  Mice with 
three copies of chromosome 16, orthologous to the critical region of human chromosome 21, 
display degeneration of cholinergic neurons in the basal forebrain similar to those with AD and 
Down syndrome.4  Therefore, overexpression of APP due to duplication may be one way to 
generate a predictable model of AD. 
The laboratory developed a novel transgenic C. elegans model of AD that displays age-
related and APP-related neurodegeneration. This model pan-neuronally expresses a single human 
APP gene (SC_APP) in addition to endogenous expression of the worm ortholog, apl-1 (amyloid 
precursor-like protein-1).  We used the C. elegans model system because of its short life span, 
transparent body, highly conserved genes, and rapid genetic manipulation.  The simplified 
nervous system of the worm, containing only 302 neurons, has been exquisitely described in 
terms of its anatomy, lineage, and intrinsic molecular profile.  The transparent body of the worm 
has made it possible to use in vivo fluorescent markers to track changes in morphology of cell 
bodies and axonal projections in live animals over the nematode life cycle from larval stage to 
death by senescence.  We showed that our model displays progressive, age-dependent 
degeneration of specific cholinergic neurons, ventral cord neuron (VC) 4 and 5. 
Researchers found that the six VC neurons, particularly VC4 and VC5 proximal to the 
vulval, are important for initiating successful egg-laying events.5  The VC4 and VC5 neurons 
have also been implicated in swim initiation.6  Therefore, egg-laying and swimming behaviors 
represent a sensitive readout of VC neuron activity in the C. elegans model system.  Using our 
model, we have previously shown that Day 3 adult worms retain significantly more eggs and 
exhibit defective swimming with respect to both AD control and wild-type animals.  These 
results suggest that neurodegeneration observed in our model might correlate with functional 
behavioral deficits in egg laying and swimming. 
Together with trackable neurodegeneration and easily measured behavior, our C. elegans 
model has proven to be useful in target identification and validation.   We identified a novel 
target, Sig2R, based on a loss-of-function model that showed reduced neurodegeneration relative 
to non-AD control animals.  While the relationship between Sig2Rs and AD has not been 
studied, it was well established that Sig2R ligands can act as agonists at the receptor to induce 
apoptosis in cancer cells.7 A preliminary screen of 5 compounds identified a Sig2R-specific 
ligand with neuroprotective benefits. This compound has since been shown to reduce cognitive 
deficits in a mouse model of AD. Specifically, we have shown that this Sig2R antagonist can 
also improve cognition in double transgenic mice homozygous for the London (V717I)8 and 
Swedish (KM670/671NL)9 mutant APP forms.  Identification and validation of a lead compound 
was an important outcome for establishing our model in future drug discovery efforts.   
Current gaps in our understanding include the mechanism through which this Sig2R-
antagonist is providing neuroprotective influence and how expression of human APP is causing 
age-dependent degeneration specifically in the VC4 and VC5 neurons.  Our hypothesis states 
that the cellular pattern of neurodegeneration seen in our C. elegans model of AD is correlated 
with accumulation of mCherry-tagged APP and that Sig2R antagonism provides protection by 
reducing the level of APP in the VC4 and VC5 neurons.  In order to test this, we first need to 
correct several imperfections in our model, namely three point mutations in the human APP gene 
and an insertion that caused the mCherry sequence to be out-of-frame.  I addressed these 
problems by 1) fixing the hAPP construct using site-directed mutagenesis and 2) inserting this 
new construct using Mos1-mediated single-copy insertion (MosSCI).  Next, I wanted to develop 
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a reverse genetic screen to find genes important for Sig2R’s functional influence on 
neurodegeneration.  I set out to test 1) whether egg laying and/or swimming behavior could 
provide a measurable phenotype necessary for rapid screening of genes and 2) if RNAi 
knockdown of the Sig2R could improve behavior in our AD model.  These goals are necessary to 
understand the mechanism by which our hit compound, the Sig2R-antagonist, provides 





The strains generated and used for this study include JPS67 and LX959.  The LX959 strain 
integrated GFP expressed specifically in the ventral cord neurons 1-6 by a ventral cord neuron-
specific promoter.  This strain also contained a lin-15B genetic background so that its genotype 
was vsIs13 IV; lin-15b(n765) X.  A single-copy of the hAPP gene on chromosome II was 
integrated into a background LX959 strain with unc-119 (ed3) rescue marker.  The genotype for 
the JPS67 strain can be described by vsIs38 II; unc-119(ed3) III; vsIs13 IV; lin-15B(n765) X.  
All strains were maintained at room temperature and fed E. Coli OP50 on NGM plates.  
Site-directed mutagenesis to repair model 
We used the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) to make specific 
changes to the DNA sequence of our hAPP gene cloned in the Gateway pDONR221 vector.  We 
repaired the three point mutations at position 585, 926, and 1082.  Primers 5’ 
CTGAAGAAAGTGACAATGTGGATTCTGCTGATG 3’ and 5’ 
CATCAGCAGAATCCACATTGTCACTTTCTTCAG 3’ contained the desired substitution 
CàT at position 585.  At position 926, primers 5’ 
CTCGAGACACCTGGGGATGAGAATGAACATGC 3’ and 5’ 
GCATGTTCATTCTCATCCCCAGGTGTCTCGAG 3’ were designed with the substitution 
GàA.  The GàA substitution at position 1082 was fixed using primers 5’ 
GTTATCCAGCATTTCCAGGAGAAAGTGGAATC 3’ and 5’ 
GATTCCACTTTCTCCTGGAAATGCTGGATAAC 3’.  To repair the frameshift in the 
mCherry sequence, primers 5’GCAGATGCAGAACTACCCAGCTTTCTTGTAC 3’ and 5’ 
GTACAAGAAAGCTGGGTAGTTCTGCATCTGC 3’ were used to delete AG at position 2082-
83.  These primers were used to synthesize mutant molecules by PCR (95°C for 50 seconds, 
60°C for 50 seconds, 68 for eight minutes) and transform them into XL 10-Gold Ultracompetent 
cells.  Colonies containing kanamycin-resistant pDONR221 vector plasmid were isolated after 
plating on kanamycin overnight (≥16 hours).  Minipreparation (Qiagen) of plasmid DNA was 
used to confirm the correct sequence by next generation sequencing in the Institute for Cellular 
and Molecular Biology (ICMB) Core Facilities.  
 
Assembly of 3’ entry clone.  
Following the Gibson Assembly protocol (E5510) developed by New England BioLabs (NEB), 
mCherry was inserted into the pDONR P2-P3 vector with unc-54 UTR.  DNA segments for the 
insert and vector were generated by PCR (95°C for 30 seconds, 55 for 30 seconds, 55-65°C 
gradient for 5:30 minutes (vector) or one minute (insert)) using primers 5’ 
GTGGCATGGATGAATTGTATAAGACTAGTTAGCATTCGTAGAATTCC 3’ and 5’ 
GTTATCTTCTTCACCCTTTGAGACTGCCCGGGCGGATCCCTCCACTTTGTA 3’, and 5’ 
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TACAAAGTGGAGGGATCCGCCCGGGCAGTCTCAAAGGGTGAAGAAGATAAC 3’ and 
5’ CTTATACAATTCATCCATGCCACCTG 3’, respectively.  To confirm the size and yield of 
our product, we ran each PCR product on an 8% agarose gel. GenElute® PCR Clean-Up Kit was 
used to purify our PCR amplification product.  This product was used in a Gibson Assembly 
Reaction (50°C for 15 minutes) to combine the DNA segments.  XL 10-Gold Ultracompetent 
cells were transformed with the assembly reaction and the plasma DNA extracted and purified by 
miniprep.   Sequence analysis by the ICMB Core Facility confirmed our final plasmid.   
 
Assembly of a transformation-ready transgene.   
We used Gateway® Technology through the Multisite LR reaction to recombine the Prab3 pan-
neuronal promoter in the 5’ entry clone, hAPP gene in the middle entry clone, and mCherry;unc-
54 UTR in the 3’ entry clone into the MosSCI destination vector pCFJ150.  The promoter had 
been cloned into the pDONR P4-P1 vector.  The LR recombination reaction was incubated 
overnight at room temperature and transformed into One Shot®TOP10 Chemically Competent 
cells.  Colonies were isolated on ampicillin plates, incubated in 3 mL of LB with 1 mM 
kanamycin overnight and prepared using QIAprep Spin Miniprep Kit for microinjection into the 
ttTi5605 C. elegans strain with a MosSCI background.  
 
Construction of Transgenic Animal 
Single-copy transgenes constructed in the PCFJ150 vector using Gateway cloning were 
introduced into ttTi5605 C. elegans following the Mos1-mediated single-copy insertion 
(MosSCI) method.  Our final construct Prab3::hAPP::unc-54UTR was microinjected into the 
distal arm of the gonad of young adults from the ttTi5605 strain (EG4450) containing the 
Drosophila Mos1 element.  The target construct contained a 2.1 kb C. briggsae unc-119 rescue 
marker and the transformation-ready transgene flanked by Mos1 site sequences for insertion at 
the Mos1 site on chromosome II by homologous recombination.  Following injection, we 
selected for animals that were moving and lacked red fluorescence in the pharynx.  The presence 
of a small percentage of animals with red pharynx suggested that the transposase worked.  
 
RNAi Preparation 
The vem-1 RNAi and empty vector plasmid pL4440 colony were selected from the Ahringer 
library (Genesequence) and grown overnight in LB with 50 µg/mL of ampicillin.  At least 24 
hours before the experiment, the vem-1 RNAi culture was seeded onto ampicillin-containing 
NGM-agar plates with 1 mM isoprophylthiogalactoside (IPTG).  Plates without IPTG were 
seeded with the L4440 empty backbone and these were considered control RNAi plates.   
 
Egg-retention Assay 
Strains LX959 and JPS67 were used.  To prepare a homogenous population of age-matched 
eggs, non-starved adult worms were treated with bleach (5M NaOH) and the eggs remaining in 
the liquid were transferred to clean NGM plates seeded with an E. coli OP50 lawn.  Eggs were 
allowed to develop for 3 days (~100 hours) so that worms reached a late larval stage 4.  About 
100 animals at this stage were transferred to RNAi and control RNAi plates and allowed to 
develop to day 2 adults (40-50 hours) at room temperature. After 60 animals were individually 
dissolved in 60 µL of 5% bleach and eggs retained within the dissolved adult animal were 




Multi-Fluid Chamber Assay 
Standard soft lithography techniques were used to fabricate devices for use as a microfluidic 
system.10  A master template was first generated with patterned features in a double layer of 50 
µM thick photoresist (100 µM total thickness)(Riston® Dry Film Photoresists, Dupont, 
Wilmington, DE) using a photomask (Cad Art Services, Brandon, OR).  All devices were 
molded from this master template in polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, 
Corning, NY).  The first layer of PDMS prepolymer was cast against the master template and 
cured in an oven for 20 min at 70°C.  An inlet/outlet was created at one end of the device using a 
nanoport.  Following this, a second layer was cast and cured for 30 min at 70°C.  PDMS was 
removed from the template and a blunt epidural needle (0.070 mm) was punched multiple times 
into the device to form fluid inlet and outlet holes.  We exposed the devices to oxygen plasma 
(120 W, 2 s) in order to irreversibly bond the devices to the coverslip.  Prior to adding animals, 
the devices were flushed a few times with ethanol, deionized water, and NGM buffer, 
respectively.  Day 2 animals were transferred from a seeded plate to an unseeded plate to clean 
off the bacteria food.  About 20-25 animals were loaded into the inlet of the device and 10µL of 
diacetyl (Sigma-Aldrich, St. Louis, MO) was immediately added to the nanoport opposite to the 
inlet where the worm were loaded.  The time started when the diacetyl was added to the device.  
At 5-minute increments for 15 minutes, the number of animals in each zone (3 total zones) was 
counted.  The strains used (LX959 and JPS67) were prepared as described above (Egg-retention 
Assay). 
 
Results –   
 
Specific changes to our AD model is necessary to visualize APP accumulation 
 
The facile genetics of the C. elegans model allowed us to easily and specifically edit the DNA 
sequence in our existing AD model so that in future studies we can visualize the human APP 
protein (hAPP) using fluorescent markers and provide information about the developmental 
timing and spatial location of gene activity relative to neurodegeneration.  We used a series of 
molecular biology techniques to repair our C. elegans model of AD with pan-neuronal 
expression of a single copy of human APP tagged with mCherry at the C-terminal.  Three point 
mutations and an insertion mutation were detected in our PCFJ150 vector recombined to contain 
Prab-3::hAPP::mCherry::unc-54-UTR.  The large 17 kb size of this construct impaired our 
success with mutagenesis. Thus, we set about to fix these problems in the smaller 8,000 kb 
pDONR 221 middle entry clone with the hAPP gene inserted.  To repair the point mutations, we 
used specifically designed primers (see Methods) to carry out three site-directed mutagenesis 
reactions to substitute CàT at position 585, GàA at position 926, and GàA at position 1082.  
A two-nucleotide insertion of AG at the end of the APP sequence caused the mCherry;unc54-
UTR construct to be out of the reading frame.  Using primers 
5’GCAGATGCAGAACTACCCAGCTTTCTTGTAC 3’ and 5’ 
GTACAAGAAAGCTGGGTAGTTCTGCATCTGC 3’, targeted deletion of AG at position 2082 
and 2083 by site-directed mutagenesis corrected for this problem.  After completion of each 
round of mutagenesis, Sanger sequencing performed in the ICMB Core Facilities confirmed 
sequences.  All four mutagenesis reactions successfully achieved the desired mutation.    
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Next we constructed a hAPP transgene with C-terminal mCherry tag that we plan to introduce in 
our C. elegans model.  We took advantage of modern modular cloning methods in order to 
assemble a fluorescent reporter construct within the 3’-untranslated region (UTR) and tag the 
hAPP gene without disrupting the original sequence context or appropriate expression patterns.  
We recombined the corrected APP entry construct with 5’ and 3’ entry clones in a single LR 
recombination reaction with the PCFJ150 destination vector.  We used a Prab-3 promoter in the 
pDONRP4-P1R vector and mCherry::unc-54-UTR in the pDONRP2-P3 vector for the 5’ 
position and 3’ position entry clones, respectively.  We used the Prab-3 promoter in order to 
achieve pan-neuronal expression of APP.  The unc-54-UTR is a common UTR used in 
transgenes to enhance expression.  The Gateway Multisite vector PCFJ150 was selected as the 
destination vector in preparation for transformation into the ttTi5605 C. elegans containing the 
Drosophila Mos1 element at the ttTi5605 site on chromosome II.  We chose this strain based on 
previous work in the laboratory and elsewhere demonstrating successful transgene integration 
following the published Mos1-mediated single-copy insertion technique.11  The PCFJ150 vector 
contains the Multisite Gateway® cassette with attR4-attR3 sequences flanked by targeting and 
selection Mos1sequences.  These Mos1 sequences are necessary for homologous recombination 
and insertion at this ttTi5605 Mos1 site.  The PCFJ150 vector also contains a 2.1 kb C. briggsae 
unc-119 fragment that rescues the unc-119(ed3) mutation in the ttTi5605 strain.  This mutation 
normally causes partial paralysis, small body and brood size, and an inability to form dauer 
larvae in response to starvation conditions.  In preparation for the LR reaction, we needed to 
construct a 5’ entry clone encoding mCherry::unc-54-UTR.  We decided to use the Gibson 
Assembly protocol to insert the mCherry gene sequence in front of the unc54-UTR sequence on 
the pDONR P2-P3 vector.  In a single reaction, we achieved a fully ligated, double-stranded 
plasmid vector ready for use.  Using this UTR vector in an LR reaction, we successfully 
produced a transformation-ready transgene as shown in Supplemental Figure S1.  
 
We made use of the well-characterized ttTi5605 strain with positive and negative markers to 
select for an insertion event in which the transgene and selection markers are incorporated into 
the genome by gene conversion.  Animals that successfully incorporated the final construct with 
the unc-119(+) gene, a positive selection marker, appeared to move and survive starvation 
conditions.  To differentiate from animals that integrated the transgene from animals that only 
carry the extrachromosmal array, we coinjected the PCFJ90 vector, which contains mCherry 
under a pharynx-specific promoter, to provide a negative selection marker.  Under fluorescence 
microscopy, we observed animals with red pharynx in our population of ttTi5605 strains.   This 
suggested that the transposase excised the Mos1 transposon and caused a double-stranded DNA 
break, which could be repaired with the transgene or the red pharynx insert.  Only animals that 
both moved and did not fluoresce red were selected.   
 
Loss-of-function Sig2R mutation normalizes behavior in AD model animals  
 
One approach to high-throughput screening (HTS) involves a chemical-to-gene approach where 
‘hit’ compounds are identified based on their ability to rescue adverse phenotypes to wild-type 
phenotypes.  Based on our previous studies showing a relationship between neurodegeneration 
and behavior, we set out to test whether functional deficits in egg laying behavior also reflect 
Sig2R’s functional influence on neurodegeneration.  As a proof of principle, we showed that 
14.77% of day-2, “middle-aged” adult control, strain LX959, animals without the extra copy of 
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hAPP retained over 17 eggs.  Control animals show a relatively clear bell-shaped curve (average 
of 14.69 eggs), whereas our AD model with a single extra copy of hAPP (SC_APP), strain 
JPS67, have a slight bimodal distribution.  As a result, there is not a large difference between 
averages in the AD (average of 16.07 eggs) and control animals, but a larger percentage of age-
matched day-2 AD animals (41.11%) that retained over 17 eggs.  Because these AD animals also 
show significant neurodegeneration at middle age, these results support our initial hypothesis 
that neurodegeneration in VC4 and VC5 neurons correlates with functional deficits in egg-laying 
behavior.  Therefore, egg laying represents both a screenable behavior and a rapid behavioral 
readout of neurodegeneration in our control and AD animals.     
 
Figure 1. Neurodegeneration is correlated temporally with defects in egg laying behavior.  
A histogram of day-2 control (blue) and AD animals (red) displays the frequency or number of 
individual animals (y-axis) that retained a discrete number of eggs (x-axis).  We show that a 
greater number of AD animals retained more than 17 eggs.  14.77% of 88 total control animals 
vs. 41.11% of 90 total AD animals retained over 17 eggs.  This is clearly observed in the 





This HTS approach is especially useful to identify genes and gene pathways when combined 
with RNA-mediated interference (RNAi).  To better understand if the neurodegeneration seen in 
our AD animals is influenced by Sig2R activity, we tested whether Sig2R knockdown by RNAi 
would normalize egg laying behavior in our AD animals.  This experiment serves as a positive 
control for our behavioral assay since we have previously shown that elimination of Sig2R is 
neuroprotective.  The Sig2R was recently identified as the progesterone receptor membrane 
component 1.12  The vem-1 gene is ortholous to the mammalian VEMA, a membrane-associated 
progesterone receptor component, and has a well-known role in axonal guidance in C. elegans.13  
Animals were fed vem-1 RNAi or pL4440 empty vector at larvae stage 4 and scored for 
functional deficits in egg-laying as day 2 adults.  We showed that RNAi treated animals were 
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fed E. coli OP50 (Supp. Figure S2).  However, animals fed pL4440 empty vector RNAi bacteria 
showed different egg laying behavior than when fed OP50 bacteria.  The relationship between 
egg laying behavior and overexpression of APP was reversed so that more control animals 
(68.66%) retained over 17 eggs than AD animals (38.04%) (Figure 2).  These results suggest that 
RNAi bacteria, not knockdown of Sig2R, affect egg laying behavior.  Consequently, our positive 
result with RNAi treatment in AD animals is unclear and egg laying is not a useful behavior for 
RNAi screens.             
 
Figure 2. Differences in bacterial strains affect the relationship between egg laying behavior 
and APP overexpression.  A histogram of control and AD animals fed pL4440 empty vector 
RNAi shows the number of animals that fall into each ‘bin’ that represents a discrete number of 
eggs.  A) Animals fed pL4440 empty vector RNAi showed different distributions in egg laying 
behavior than when fed E. coli OP50.  68.66% of 67 total control animals and 38.04% of 92 total 
AD animals retained over 17 eggs.  The control distribution (average of 20.76 eggs) was shifted 
to the right whereas the B) AD distribution (average of 15.64 eggs) was shifted to the left.  These 




We next investigated whether locomotion may represent an alternative behavioral readout of VC 
neuron function in our RNAi screen.  First, we tested whether swimming and crawling are 
affected in our AD model.  We developed a microfluidic chamber assay where worms 
alternatively swim in open areas and crawl through a field of pillars.  Animals are injected at the 
start 6.3 mm from the first pillar field as shown in the experimental set up in Supp. Figure S3.  
The goal of the design was to have animals race to an attractant at the other end so that defects in 
motility and transitioning between swimming and crawling will differentiate AD animals from 
non-AD control animals.  An attractant gradient of 10 µL 1:1000 diacetyl was sufficient to 
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Significantly less (p < 0.05) day-2 AD animals were able to make it into the third zone nearest 
the ‘goal’ after the same time period (Figure 3).  For each trial, the percentage of animals in each 
zone was averaged at each 5-minute time point and a t-test for significance was performed.  The 
inability of AD animals to perform basic locomotor tasks suggests that the ventral cord neurons 
are necessary for proper swimming, crawling, and/or gait transitions.  Additionally, animals 
treated with vem-1 RNAi were capable of reaching the goal as frequently as non-AD control 
animals (Figure 4).  It is important to note that although we did not calculate statistical 
significance (p>0.1) between the untreated AD animals and AD animals treated with vem-1 
RNAi, we do notice a clear difference between these groups in zone 3 after 15 minutes from the 
start time.  This clear trend in our AD animals toward control levels suggests that swimming is a 
useful behavior in RNAi screening.  We plan to perform additional trials with all control groups 
(non-AD animals with vem-1 RNAi or pL4440 RNAi) and larger sample sizes in order to 
statistically prove that knockdown of Sig2R can reverse abnormal swimming behavior to control 
phenotypes.  We expect to see a similar trend in our AD animals treated with vem-1 RNAi when 
compared to non-AD control animals treated with pL4440 RNAi.  Overall, these results support 
our hypothesis that loss of Sig2R function is neuroprotective and thereby sustains normal 
swimming, crawling, and gait transitions.    
 
Figure 3.  Animals with an extra copy of hAPP show functional deficits in a multi-fluid 
chamber assay.  The percent number of animals in each zone (x-axis) at 15 minutes after 
starting the race was averaged across three trials and recorded on the y-axis.  From several 
different trials, a total of 87 and 84 animals of AD and control, respectively, were scored at 5-
minute increments after diacetyl was added (time = 0).  A 15-minute time period was sufficient 
for significantly more wild-type animals to reach zone 3 relative to AD animals as measured by 
t-test (p<0.05).  There was no significant difference in animals that reached zone 1 in the same 
time period.    
 
 
Figure 4. RNAi knockdown of Sig2R normalizes multi-fluid chamber behavior in AD 
animals.  Untreated AD animals and AD animals treated with vem-1 RNAi (total of 57 animals) 
at larval stage 4 were scored as day-2 adults. The percent number of untreated and treated AD 
animals in each zone (x-axis) at 15 minutes after starting the race were averaged across three 
trials and recorded on the y-axis.  43% of vem-1 RNAi treated AD animals were able to reach the 
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third zone after 15 minutes.  Similar results were recorded with non-AD control animals (53% 
reached zone 3), suggesting that knockdown of Sig2R modulates motility and/or transition 
between swimming and crawling.  No statistical significance using t-test (p>0.1) was found 
between the two groups in each zone; this is most likely due to the low sample size of each 
group.     
 
Discussion  –  
 
There is no existing model powerful enough to answer all the questions surrounding the 
century old debate of AD.  In this study, we set out to establish the C. elegans model system for 
future drug discovery efforts in AD.  Despite only having 959 somatic cells, the C. elegans 
system is a sophisticated and complex multicellular organism with highly conserved protein 
functional and structural properties.  We confirmed and expanded upon previous work in the 
laboratory demonstrating the use of a novel transgenic C. elegans model of AD for large-scale 
target validation and high throughput compound screens that would otherwise be impossible in 
higher order mammalian models.  
We have shown that overexpression of a key, highly conserved genes can result in easily 
measured phenotypes.  Both locomotion and egg-laying behavior were altered in our in vivo 
model upon pan-neuronal expression of an extra copy of human APP.  The goal of our 
behavioral studies was to identify a screenable behavior that could be used in a large-scale RNAi 
screen for important genes mediating Sig2R influence on neurodegeneration.  It is important to 
understand the mechanism of drug action in order to avoid unanticipated side effects in later 
clinical trials.  We found that although egg laying behavior can be rapidly scored, cheap to 
prepare, and easy to replicate, it is adversely altered by bacterial strains necessary for RNAi 
studies.  Alternately, we demonstrated that locomotion efficiency could be a rapid and sensitive 
behavioral readout of neurodegeneration that is needed to facilitate high quality and high-
throughput screens.   
Our AD model showed impaired motor skills necessary for efficient gait transition and 
swimming.  These results were measurable in animals known to display significant 
neurodegeneration in VC4 and VC5 neurons at day 2. AD animals were not able to navigate our 
multi fluid chamber at the same efficiency level of control animals that could quickly travel 
through alternating zones of open areas and fields of pillars within 15 minutes.  The ability to 
differentiate between control and AD animals was an important outcome of this behavioral 
assay.  We propose that the inability of our AD animals to produce efficient movement is due to 
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defective production and control of locomotor gaits by central nervous system neurons, 
specifically the VC neurons.  Coincidental neurodegeneration of VC4 and VC5 in our model, 
therefore, seems to be sufficient to cause functional defects in motor skills that can be quickly 
and easily scored.  
This sensitive behavioral correlate of neurodegeneration demonstrated by our AD model 
in our multi-fluid chamber suggests that we could use this assay to find genes important for 
Sig2R-mediated modulation of neurodegeneration.  To do so, we plan to perform an RNAi 
knockdown screen of potentially relevant genes. The ability use RNAi  knockdown at later 
developmental stages or even beyond development in the worm greatly facilitates functional 
genomic studies of genes important in aging.  One way to manipulate Sig2R function is also with 
RNAi. However, it has been shown that the efficiency of knockdown by RNAi in worms is 
reduced when targeting multiple genes.14  Instead, we will need to manipulate Sig2R function 
pharmacologically. The multi-fluid chamber assay can support this need as animals are 
accessible to simultaneous treatment with RNAi and a known compound.  Thus, we can treat 
animals with a Sig2R antagonist or agonist by soaking to influence neurodegeneration in either 
direction, while simultaneously using RNAi to knockdown a single gene in our AD model.  
Employing our multi-chamber behavioral readout, we then can determine whether knockdown of 
the single gene could either “break” or rescue the influence of Sig2R modulation on the AD 
phenotype.  In this way, we will be able to develop an understanding of the mechanism of drug 
action.   
To achieve our second goal of investigating the causal relationship between APP 
accumulation and neurodegeneration in VC4 and VC5 neurons, we fixed the hAPP construct in 
our AD model.  Since the Sig2R antagonist has been shown to be protective against 
neurodegeneration, we reasoned that this protection might come about by reduction of APP 
levels in VC neurons.  This can only be tested in our new model strain, in which the mCherry 
gene is in reading frame with hAPP. We will use this model to reconfirm our neurodegeneration 
and behavior results and provide more information about the role of APP in neurodegeneration 
and cell protection by Sig2R antagonism.   
The present study is important for guiding future high-throughput screening studies 
investigating novel therapeutic targets for the treatment of AD.  Instead of screening for AD-
specific functional activity in a cell-based assay, we demonstrated that our in vivo model of AD 
could be used to select for genes important for Sig2R’s influence on neurodegeneration.  From a 
reductionist approach, our in vivo model system represents an enormous advantage to the 
pharmaceutical industry.  It is easily maintained in the laboratory and can rapidly develop from 
egg to adult within 3 days, producing about 300 progeny each.  In this short period of time, 
millions of animals can be produced and analyzed in microtitre plates or in a single well of a 96-
well plate with large sample sizes.  The sensitivity of the worm to RNAi treatment further 
accelerates the target identification and validation process that is necessary for pharmaceutical 
development.  We plan to use an RNAi screening technique to probe the mechanism of action of 
our novel Sig2R ligands in our AD worm.  Towards this end, we have produced a behavioral 
assay, locomotor performance in a multi-fluid chamber, to screen for the effects of single gene 
knockdown on Sig2R ligand efficacy. More broadly, this behavioral correlate of 
neurodegeneration holds the potential to accelerate target validation and drug discovery for 
neurodegenerative diseases into higher order mammalian systems and humans.  Continued work 
in our new and improved in vivo model will be needed to establish its use in further drug 
discovery efforts.   
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Supplemental Information. 
Supplemental information includes three figures providing results from the final sequencing 
analysis of our transformation-ready transgene and from the Egg-retention Assay using vem-1 
RNAi treatment.  In addition, we have provided a diagram of the device used in our Multi-fluid 
Chamber Assay.   
 
Supplemental Figure S1. The final sequence for the transformation ready-transgene contained 
the 3’ Prab3 promoter, hAPP gene, C-terminal tag with mCherry sequence (yellow), and 5’ unc-
54-UTR (green).  The APP construct contained the desired mutations that repaired the three 
point mutations (at position 585, 926, and 1082; highlighted in blue) and the insertion at position 



















































































Supplemental Figure S2. RNAi knockdown of Sig2R/vem-1 normalizes swimming behavior in 
AD animals.  Cumulative results from three separate trials show that animals fed A) vem-1 RNAi 
at larval stage 4 (120 total animals) retained less eggs than animals fed B) pL4440 empty vector 
(left; 122 total animals).  A left-shifted change toward non-AD control egg laying behavior 




Supplemental Figure S3.  Experimental design for the multi-fluid chamber assay.  The first area 
(black) has pillars with a larger diameter than the pillars in the other 3 areas (grey).  The space 
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